When pregnancy is detected, discontinue azilsartan medoxomil as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] .
Azilsartan medoxomil is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs...
The recommended dose in adults is 80 mg taken orally once daily. Consider a starting dose of 40 mg for patients who are treated with high doses of diuretics. Do not repackage azilsartan medoxomil. Dispense and store azilsartan medoxomil in its original container to protect azilsartan medoxomil from light and moisture.
Azilsartan Medoxomil Tablets, USP are unscored and white to nearly white, debossed with "ASL" on one side and "40" or "80" on the other. Tablet NDC 52536-xxx-xx Bottle/30 40 mg 004-03 80 mg 008-03 Storage Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Keep container tightly closed. Protect from moisture and light. Do not repackage; dispense and store in o...
www.fda.gov/medwatchAzilsartan medoxomil is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with azilsartan medoxomil.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
Azilsartan medoxomil may be used alone or in combination with other antihypertensive agents.
The recommended dose in adults is 80 mg taken orally once daily. Consider a starting dose of 40 mg for patients who are treated with high doses of diuretics.
Do not repackage azilsartan medoxomil. Dispense and store azilsartan medoxomil in its original container to protect azilsartan medoxomil from light and moisture.
Azilsartan Medoxomil Tablets, USP are supplied as white to nearly white round tablets in the following dosage strengths:
Do not coadminister aliskiren-containing products with azilsartan medoxomil in patients with diabetes [see Drug Interactions (7)].
Azilsartan medoxomil can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue azilsartan medoxomil as soon as possible [see Use in Specific Populations (8.1)].
In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with azilsartan medoxomil. Correct volume or salt depletion prior to administration of azilsartan medoxomil, or start treatment at 40 mg. If hypotension does occur, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized.
As a consequence of inhibiting the renin-angiotensin system, changes in renal function may be anticipated in susceptible individuals treated with azilsartan medoxomil. In patients whose renal function may depend on the activity of the renin-angiotensin system (e.g., patients with severe congestive heart failure, renal artery stenosis, or volume depletion), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been associated with oliguria or progressive azotemia and rarely with acute renal failure and death. Similar results may be anticipated in patients treated with azilsartan medoxomil [see Drug Interactions (7), Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)].
In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen have been reported. There has been no long-term use of azilsartan medoxomil in patients with unilateral or bilateral renal artery stenosis, but similar results may be expected.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
A total of 4814 patients were evaluated for safety when treated with azilsartan medoxomil at doses of 20, 40, or 80 mg in clinical trials. This includes 1704 patients treated for at least six months; of these, 588 were treated for at least one year.
Treatment with azilsartan medoxomil was well-tolerated with an overall incidence of adverse reactions similar to placebo. The rate of withdrawals due to adverse events in placebo-controlled monotherapy and combination therapy trials was 2.4% (19/801) for placebo, 2.2% (24/1072) for azilsartan medoxomil 40 mg, and 2.7% (29/1074) for azilsartan medoxomil 80 mg. The most common adverse event leading to discontinuation, hypotension/orthostatic hypotension, was reported by 0.4% (8/2146) patients randomized to azilsartan medoxomil 40 mg or 80 mg compared to 0% (0/801) patients randomized to placebo. Generally, adverse reactions were mild, not dose related, and similar regardless of age, gender, and race.
In placebo-controlled monotherapy trials, diarrhea was reported up to 2% in patients treated with azilsartan medoxomil 80 mg daily compared with 0.5% of patients on placebo.
Other adverse reactions with a plausible relationship to treatment that have been reported with an incidence of ≥0.3% and greater than placebo in more than 3300 patients treated with azilsartan medoxomil in controlled trials are listed below:
Gastrointestinal Disorders: nausea
General Disorders and Administration Site Conditions: asthenia, fatigue
Musculoskeletal and Connective Tissue Disorders: muscle spasm
Nervous System Disorders: dizziness, dizziness postural
Respiratory, Thoracic, and Mediastinal Disorders: cough
The following adverse reactions have been identified during the postmarketing use of azilsartan medoxomil. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
In patients who are elderly, volume-depleted (including those on diuretic therapy), or who have compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including azilsartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving azilsartan and NSAID therapy.
The antihypertensive effect of angiotensin II receptor antagonists, including azilsartan, may be attenuated by NSAIDs, including selective COX-2 inhibitors.
Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on azilsartan medoxomil and other agents that affect the RAS.
Do not coadminister aliskiren with azilsartan medoxomil in patients with diabetes. Avoid use of aliskiren with azilsartan medoxomil in patients with renal impairment (GFR <60 mL/min).
Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor agonists. Monitor serum lithium levels during concomitant use.
Risk Summary
Azilsartan medoxomil can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death (see Clinical Considerations). Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents.
When pregnancy is detected, discontinue azilsartan medoxomil as soon as possible.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Clinical Considerations
Disease-associated maternal and/or embryo/fetal risk
Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly.
Fetal/Neonatal adverse reactions
Oligohydramnios in pregnant women who use drugs affecting the renin-angiotensin system in the second and third trimesters can result in the following: reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension and death.
Perform serial ultrasound examinations to assess the intra-amniotic environment. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury.
Closely observe infants with histories of in utero exposure to azilsartan medoxomil for hypotension, oliguria, and hyperkalemia. In neonates with a history of in utero exposure to azilsartan medoxomil, if oliguria or hypotension occurs, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function.
Data
Animal Data
In peri- and postnatal rat development studies, adverse effects on pup viability, delayed incisor eruption and dilatation of the renal pelvis along with hydronephrosis were seen when azilsartan medoxomil was administered to pregnant and nursing rats at 1.2 times the MRHD on a mg/m2 basis. Reproductive toxicity studies indicated that azilsartan medoxomil was not teratogenic when administered at oral doses up to 1000 mg azilsartan medoxomil/kg/day to pregnant rats (122 times the MRHD on a mg/m2 basis) or up to 50 mg azilsartan medoxomil/kg/day to pregnant rabbits (12 times the MRHD on a mg/m2 basis). M-II also was not teratogenic in rats or rabbits at doses up to 3000 mg M-II/kg/day. Azilsartan crossed the placenta and was found in the fetuses of pregnant rats and was excreted into the milk of lactating rats.
Risk Summary
There is limited information regarding the presence of azilsartan in human milk, the effects on the breastfed infant, or the effects on milk production. Azilsartan is present in rat milk. Because of the potential for adverse effects on the nursing infant, advise a nursing woman that breastfeeding is not recommended during treatment with azilsartan medoxomil.
Safety and effectiveness in pediatric patients have not been established.
Use of azilsartan medoxomil is not recommended in children less than 2 years of age. It is not known whether post-natal use of azilsartan in patients less than 2 years of age, before maturation of kidney function is complete, has a long-term deleterious effect on the kidney.
Juvenile Animal Studies
In juvenile rat studies, dosing with azilsartan starting on post-natal day 14 (equivalent to a neonate with morphologically and functionally immature kidneys) resulted in increased incidence of edema of the renal papilla at the end of 4-week recovery period that was non-reversible. These findings occurred in the high-dose group (10 mg/kg) and were not observed in juvenile rats dosed starting on post-natal day 21 (equivalent to a human approximately 2 years of age) or adult rats.
Dose adjustment is not required in patients with mild-to-severe renal impairment or end-stage renal disease. Patients with moderate to severe renal impairment are more likely to report abnormally high serum creatinine values.
No dose adjustment with azilsartan medoxomil is necessary in elderly patients. Of the total patients in clinical studies with azilsartan medoxomil, 26% were elderly (65 years of age and older); 5% were 75 years of age and older. Abnormally high serum creatinine values were more likely to be reported for patients age 75 or older. No other differences in safety or effectiveness were observed between elderly patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see Clinical Pharmacology (12.3)].
No dose adjustment is necessary for subjects with mild or moderate hepatic impairment. Azilsartan medoxomil has not been studied in patients with severe hepatic impairment [see Clinical Pharmacology (12.3)].
Limited data are available related to overdosage in humans. During controlled clinical trials in healthy subjects, once-daily doses up to 320 mg of azilsartan medoxomil were administered for seven days and were well tolerated. In the event of an overdose, supportive therapy should be instituted as dictated by the patient's clinical status. Azilsartan is not dialyzable [see Clinical Pharmacology (12.3)].
Azilsartan medoxomil, a prodrug, is hydrolyzed to azilsartan in the gastrointestinal tract during absorption. Azilsartan is an angiotensin II receptor blocker.
The drug substance used in the drug product formulation is the potassium salt of azilsartan medoxomil, also known by the US accepted name of azilsartan kamedoxomil and is chemically described as (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate monopotassium salt.
Its empirical formula is C30H23KN4O8 and its structural formula is:
Azilsartan kamedoxomil is a white to nearly white powder with a molecular weight of 606.62. It is practically insoluble in water and freely soluble in methanol.
Azilsartan Medoxomil Tablets, USP are available for oral use as tablets. The tablets have a characteristic odor. Each azilsartan medoxomil tablet contains 42.68 or 85.36 mg of azilsartan kamedoxomil, which is equivalent to containing 40 mg or 80 mg respectively, of azilsartan medoxomil and the following inactive ingredients: mannitol, fumaric acid, sodium hydroxide, hydroxypropyl cellulose, croscarmellose sodium, microcrystalline cellulose, and magnesium stearate.
Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzymes (ACE, kinase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Azilsartan medoxomil is an orally administered prodrug that is rapidly converted by esterases during absorption to the active moiety, azilsartan. Azilsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is, therefore, independent of the pathway for angiotensin II synthesis.
An AT2 receptor is also found in many tissues, but this receptor is not known to be associated with cardiovascular homeostasis. Azilsartan has more than a 10,000-fold greater affinity for the AT1 receptor than for the AT2 receptor.
Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of hypertension. ACE inhibitors also inhibit the degradation of bradykinin, a reaction catalyzed by ACE. Because azilsartan does not inhibit ACE (kinase II), it should not affect bradykinin levels. Whether this difference has clinical relevance is not yet known. Azilsartan does not bind to or block other receptors or ion channels known to be important in cardiovascular regulation.
Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of azilsartan on blood pressure.
Azilsartan inhibits the pressor effects of an angiotensin II infusion in a dose-related manner. An azilsartan single dose equivalent to 32 mg azilsartan
medoxomil inhibited the maximal pressor effect by approximately 90% at peak, and approximately 60% at 24 hours. Plasma angiotensin I and II concentrations and plasma renin activity increased while plasma aldosterone concentrations decreased after single and repeated administration of azilsartan medoxomil to healthy subjects; no clinically significant effects on serum potassium or sodium were observed.
Effect on Cardiac Repolarization
A thorough QT/QTc study was conducted to assess the potential of azilsartan to prolong the QT/QTc interval in healthy subjects. There was no evidence of QT/QTc prolongation at a dose of 320 mg of azilsartan medoxomil.
Absorption
Azilsartan medoxomil is hydrolyzed to azilsartan, the active metabolite, in the gastrointestinal tract during absorption. Azilsartan medoxomil is not detected in plasma after oral administration. Dose proportionality in exposure was established for azilsartan in the azilsartan medoxomil dose range of 20 mg to 320 mg after single or multiple dosing.
The estimated absolute bioavailability of azilsartan following administration of azilsartan medoxomil is approximately 60%. After oral administration of azilsartan medoxomil, peak plasma concentrations (Cmax) of azilsartan are reached within 1.5 to 3 hours. Food does not affect the bioavailability of azilsartan.
Distribution
The volume of distribution of azilsartan is approximately 16 L. Azilsartan is highly bound to human plasma proteins (>99%), mainly serum albumin. Protein binding is constant at azilsartan plasma concentrations well above the range achieved with recommended doses.
In rats, minimal azilsartan-associated radioactivity crossed the blood-brain barrier. Azilsartan passed across the placental barrier in pregnant rats and was distributed to the fetus.
Metabolism and Elimination
Azilsartan is metabolized to two primary metabolites. The major metabolite in plasma is formed by O-dealkylation, referred to as metabolite M-II, and the minor metabolite is formed by decarboxylation, referred to as metabolite M-I. Systemic exposures to the major and minor metabolites in humans were approximately 50% and less than 1% of azilsartan, respectively. M-I and M-II do not contribute to the pharmacologic activity of azilsartan medoxomil. The major enzyme responsible for azilsartan metabolism is CYP2C9.
Following an oral dose of 14C-labeled azilsartan medoxomil, approximately 55% of radioactivity was recovered in feces and approximately 42% in urine, with 15% of the dose excreted in urine as azilsartan. The elimination half-life of azilsartan is approximately 11 hours and renal clearance is approximately 2.3 mL/min. Steady-state levels of azilsartan are achieved within five days, and no accumulation in plasma occurs with repeated once-daily dosing.
Specific Populations
The effect of demographic and functional factors on the pharmacokinetics of azilsartan was studied in single and multiple dose studies. Pharmacokinetic measures indicating the magnitude of the effect on azilsartan are presented in Figure 1 as change relative to reference (test/reference). Effects are modest and do not call for dosage adjustment.
Figure 1. Impact of intrinsic factors on the pharmacokinetics of azilsartan
Drug Interactions
No clinically significant drug interactions have been observed in studies of azilsartan medoxomil or azilsartan given with amlodipine, antacids, chlorthalidone, digoxin, fluconazole, glyburide, ketoconazole, metformin, pioglitazone, and warfarin. Therefore, azilsartan medoxomil may be used concomitantly with these medications.
Carcinogenesis
Azilsartan medoxomil was not carcinogenic when assessed in 26-week transgenic (Tg.rasH2) mouse and two-year rat studies. The highest doses tested (450 mg azilsartan medoxomil/kg/day in the mouse and 600 mg azilsartan medoxomil/kg/day in the rat) produced exposures to azilsartan that are 12 (mice) and 27 (rats) times the average exposure to azilsartan in humans given the maximum recommended human dose (MRHD, 80 mg azilsartan medoxomil/day). M-II was not carcinogenic when assessed in 26-week Tg.rasH2 mouse and two-year rat studies. The highest doses tested (approximately 8000 mg M-II/kg/day [males] and 11,000 mg M-II/kg/day [females] in the mouse and 1000 mg M-II/kg/day [males] and up to 3000 mg M-II/kg/day [females] in the rat) produced exposures that are, on average, about 30 (mice) and seven (rats) times the average exposure to M-II in humans at the MRHD.
Mutagenesis
Azilsartan medoxomil, azilsartan, and M-II were positive for structural aberrations in the Chinese Hamster Lung Cytogenetic Assay. In this assay, structural chromosomal aberrations were observed with the prodrug, azilsartan medoxomil, without metabolic activation. The active moiety, azilsartan was also positive in this assay both with and without metabolic activation. The major human metabolite, M-II was also positive in this assay during a 24-hour assay without metabolic activation.
Azilsartan medoxomil, azilsartan, and M-II were devoid of genotoxic potential in the Ames reverse mutation assay with Salmonella typhimurium and Escherichia coli, the in vitro Chinese Hamster Ovary Cell forward mutation assay, the in vitro mouse lymphoma (tk) gene mutation test, the ex vivo unscheduled DNA synthesis test, and the in vivo mouse and/or rat bone marrow micronucleus assay.
Impairment of Fertility
There was no effect of azilsartan medoxomil on the fertility of male or female rats at oral doses of up to 1000 mg azilsartan medoxomil/kg/day (6000 mg/m2 [approximately 122 times the MRHD of 80 mg azilsartan medoxomil/60 kg on a mg/m2 basis]). Fertility of rats also was unaffected at doses of up to 3000 mg M-II/kg/day.
The antihypertensive effects of azilsartan medoxomil have been demonstrated in a total of seven double-blind, randomized studies, which included five placebo-controlled and four active comparator-controlled studies (not mutually exclusive). The studies ranged from six weeks to six months in duration, at doses ranging from 20 mg to 80 mg once daily. A total of 5941 patients (3672 given azilsartan medoxomil, 801 given placebo, and 1468 given active comparator) with mild, moderate or severe hypertension were studied. Overall, 51% of patients were male and 26% were 65 years or older; 67% were white and 19% were black.
Two 6-week, randomized, double-blind studies compared the effect on blood pressure of azilsartan medoxomil at doses of 40 mg and 80 mg, with placebo and with active comparators. Blood pressure reductions compared to placebo based on clinic blood pressure measurements at trough and 24-hour mean blood pressure by ambulatory blood pressure monitoring (ABPM) are shown in Table 1 for both studies. Azilsartan medoxomil, 80 mg, was statistically superior to placebo and active comparators for both clinic and 24-hour mean blood pressure measurements.
| Table 1. Placebo Corrected Mean Change from Baseline in Systolic/Diastolic Blood Pressure at 6 Weeks (mm Hg) | ||||
| | Study 1 N=1285 | Study 2 N=989 | ||
| | Clinic Blood Pressure (Mean Baseline 157.4/92.5) | 24 Hour Mean by ABPM (Mean Baseline 144.9/88.7) | Clinic Blood Pressure (Mean Baseline 159.0/91.8) | 24 Hour Mean by ABPM (Mean Baseline 146.2/87.6) |
| Azilsartan medoxomil 40 mg | -14.6/-6.2 | -13.2/-8.6 | -12.4/-7.1 | -12.1/-7.7 |
| Azilsartan medoxomil 80 mg | -14.9/-7.5 | -14.3/-9.4 | -15.5/-8.6 | -13.2/-7.9 |
| Olmesartan 40 mg | -11.4/-5.3 | -11.7/-7.7 | -12.8/-7.1 | -11.2/-7.0 |
| Valsartan 320 mg | -9.5/-4.4 | -10.0/-7.0 | | |
In a study comparing azilsartan medoxomil to valsartan over 24 weeks, similar results were observed.
Most of the antihypertensive effect occurs within the first two weeks of dosing.
Figure 2 shows the 24-hour ambulatory systolic and diastolic blood pressure profiles at endpoint.
Figure 2. Mean Ambulatory Blood Pressure at 6 Weeks by Dose and Hour
Other studies showed similar 24-hour ambulatory blood pressure profiles.
Azilsartan medoxomil has a sustained and consistent antihypertensive effect during long-term treatment, as shown in a study that randomized patients to placebo or continued azilsartan medoxomil after 26 weeks. No rebound effect was observed following the abrupt cessation of azilsartan medoxomil therapy.
Azilsartan medoxomil was effective in reducing blood pressure regardless of the age, gender, or race of patients, but the effect, as monotherapy, was smaller, approximately half, in black patients, who tend to have low renin levels. This has been generally true for other angiotensin II antagonists and ACE inhibitors.
Azilsartan medoxomil has about its usual blood pressure lowering effect size when added to a calcium channel blocker (amlodipine) or a thiazide-type diuretic (chlorthalidone).
There are no trials of azilsartan medoxomil demonstrating reductions in cardiovascular risk in patients with hypertension, but at least one pharmacologically similar drug has demonstrated such benefits.
Azilsartan Medoxomil Tablets, USP are unscored and white to nearly white, debossed with "ASL" on one side and "40" or "80" on the other.
| Tablet | NDC 52536-xxx-xx |
| Bottle/30 | |
| 40 mg | 004-03 |
| 80 mg | 008-03 |
Storage
Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Keep container tightly closed. Protect from moisture and light. Do not repackage; dispense and store in original container.
Advise the patient to read the FDA-approved patient labeling (Patient Information)
Pregnancy
Tell female patients of childbearing potential about the consequences of exposure to azilsartan medoxomil during pregnancy. Discuss treatment options with women planning to become pregnant. Tell patients to report pregnancies to their physicians as soon as possible.
Patient Information
Azilsartan Medoxomil
(AY-zil-SAR-tan me-DOX-oh-mil)
Tablets
Read this Patient Information leaflet before you start taking azilsartan medoxomil and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment.
What is the most important information I should know about azilsartan medoxomil?
What is azilsartan medoxomil?
Azilsartan medoxomil is a prescription medicine called an angiotensin II receptor blocker (ARB) used to treat high blood pressure (hypertension) in adults.
Your doctor may prescribe other medicines for you to take along with azilsartan medoxomil to treat your high blood pressure.
It is not known if azilsartan medoxomil is safe and effective in children under 18 years of age.
What should I tell my doctor before taking azilsartan medoxomil?
Before you take azilsartan medoxomil, tell your doctor if you:
Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.
Especially tell your doctor if you take:
Ask your doctor if you are not sure if you are taking a medicine listed above.
Know the medicines you take. Keep a list of them and show it to your doctor or pharmacist when you get a new medicine.
How should I take azilsartan medoxomil?
What are the possible side effects of azilsartan medoxomil?
Azilsartan medoxomil may cause side effects, including:
If you feel faint or dizzy, lie down and call your doctor right away.
These are not all the possible side effects with azilsartan medoxomil. Tell your doctor if you have any side effect that bothers you or that does not go away.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How do I store azilsartan medoxomil?
Keep azilsartan medoxomil and all medicines out of the reach of children.
General information about azilsartan medoxomil.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not give azilsartan medoxomil to other people, even if they have the same symptoms you have. It may harm them.
This Patient Information leaflet summarizes the most important information about azilsartan medoxomil. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about azilsartan medoxomil that is written for health professionals.
For more information, call 1-877-495-6856.
What is high blood pressure (hypertension)?
Blood pressure is the force in your blood vessels when your heart beats and when your heart rests. You have high blood pressure when the force is too great.
High blood pressure makes the heart work harder to pump blood through the body and causes damage to the blood vessels. Azilsartan medoxomil tablets can help your blood vessels relax so your blood pressure is lower. Medicines that lower your blood pressure may lower your chance of having a stroke or heart attack.
What are the ingredients in azilsartan medoxomil?
Active ingredient: azilsartan medoxomil
Inactive ingredients: mannitol, fumaric acid, sodium hydroxide, hydroxypropyl cellulose, croscarmellose sodium, microcrystalline cellulose, and magnesium stearate.
Manufactured by:
Takeda
Ireland
Manufactured for:
Wilshire Pharmaceuticals, Inc.
Atlanta, GA 30328 USA
Rev.00 JAN/2024
NDC 52536-004-03
30 Tablets
Azilsartan Medoxomil Tablets
40 mg
Rx Only
NDC 52536-008-03
30 Tablets
Azilsartan Medoxomil Tablets
80 mg
Rx Only
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1091646 | azilsartan medoxomil 40 MG Oral Tablet | PSN | 1 |
| 1091652 | azilsartan medoxomil 80 MG Oral Tablet | PSN | 1 |
| 1091646 | azilsartan medoxomil 40 MG Oral Tablet | SCD | 1 |
| 1091652 | azilsartan medoxomil 80 MG Oral Tablet | SCD | 1 |
| 1091646 | azilsartan medoxomil 40 MG (equivalent to azilsartan kamedoxomil 42.68 MG) Oral Tablet | SY | 1 |
| 1091652 | azilsartan medoxomil 80 MG (equivalent to azilsartan kamedoxomil 85.36 MG) Oral Tablet | SY | 1 |
| Class | Version | Type | Effective |
|---|---|---|---|
| AZILSARTAN Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 0450926f-f624-49c2-83be-42807e8fbcd5 | Product name | 1 | 20251113 |
| 9c73251d-aa60-4cfe-993e-64d90dc1df32 | Product name | 1 | 20201015 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 52536-004-03 | Azilsartan Medoxomil | 30 in 1 BOTTLE | TABLET | 30 | 1 | |
| 52536-008-03 | Azilsartan Medoxomil | 30 in 1 BOTTLE | TABLET | 30 | 1 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 52536-004-03 | EA - Each | 52536-004 | 45eccbf2-3bc2-415d-9d7d-69682848a365 | 1 | 2026-05-22 |
| 52536-008-03 | EA - Each | 52536-008 | fcefe742-0b80-470d-ba9c-d14857e41145 | 1 | 2026-05-22 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 52536-004 | 52536-004-03 |
| 52536-008 | 52536-008-03 |
Every source-derived ingredient row is available through these pages.
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N200796-001 | EDARBI | AZILSARTAN KAMEDOXOMIL | EQ 40MG MEDOXOMIL | TABLET / ORAL | AB | RLD | 2011-02-25 |
| N200796-002 | EDARBI | AZILSARTAN KAMEDOXOMIL | EQ 80MG MEDOXOMIL | TABLET / ORAL | AB | RLD, RS | 2011-02-25 |
| Application-product | TE code |
|---|---|
| N200796-001 | AB |
| N200796-002 | AB |
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N200796-001 | 9066936 | 2028-03-26 | Drug product | 2015-07-30 | |
| N200796-002 | 9066936 | 2028-03-26 | Drug product | 2015-07-30 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N200796-001 | EDARBI | EQ 40MG MEDOXOMIL | TABLET / ORAL | AB | RLD | 2011-02-25 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N200796-002 | EDARBI | EQ 80MG MEDOXOMIL | TABLET / ORAL | AB | RLD, RS | 2011-02-25 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | N200796-001 | EDARBI | EQ 40MG MEDOXOMIL | TABLET / ORAL | AB | RLD | 2011-02-25 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N200796-002 | EDARBI | EQ 80MG MEDOXOMIL | TABLET / ORAL | AB | RLD, RS | 2011-02-25 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N200796-001 | EDARBI | EQ 40MG MEDOXOMIL | TABLET / ORAL | AB | RLD | 2011-02-25 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N200796-002 | EDARBI | EQ 80MG MEDOXOMIL | TABLET / ORAL | AB | RLD, RS | 2011-02-25 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N200796-001 | EDARBI | EQ 40MG MEDOXOMIL | TABLET / ORAL | RLD | 2011-02-25 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N200796-002 | EDARBI | EQ 80MG MEDOXOMIL | TABLET / ORAL | RLD, RS | 2011-02-25 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N200796-001 | EDARBI | EQ 40MG MEDOXOMIL | TABLET / ORAL | RLD | 2011-02-25 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N200796-002 | EDARBI | EQ 80MG MEDOXOMIL | TABLET / ORAL | RLD, RS | 2011-02-25 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N200796-001 | EDARBI | EQ 40MG MEDOXOMIL | TABLET / ORAL | RLD | 2011-02-25 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N200796-002 | EDARBI | EQ 80MG MEDOXOMIL | TABLET / ORAL | RLD, RS | 2011-02-25 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N200796-001 | EDARBI | EQ 40MG MEDOXOMIL | TABLET / ORAL | RLD | 2011-02-25 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N200796-002 | EDARBI | EQ 80MG MEDOXOMIL | TABLET / ORAL | RLD, RS | 2011-02-25 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N200796-001 | EDARBI | EQ 40MG MEDOXOMIL | TABLET / ORAL | RLD | 2011-02-25 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N200796-002 | EDARBI | EQ 80MG MEDOXOMIL | TABLET / ORAL | RLD, RS | 2011-02-25 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N200796-001 | EDARBI | EQ 40MG MEDOXOMIL | TABLET / ORAL | RLD | 2011-02-25 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N200796-002 | EDARBI | EQ 80MG MEDOXOMIL | TABLET / ORAL | RLD, RS | 2011-02-25 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N200796-001 | EDARBI | EQ 40MG MEDOXOMIL | TABLET / ORAL | RLD | 2011-02-25 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N200796-002 | EDARBI | EQ 80MG MEDOXOMIL | TABLET / ORAL | RLD, RS | 2011-02-25 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N200796-001 | EDARBI | EQ 40MG MEDOXOMIL | TABLET / ORAL | RLD | 2011-02-25 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N200796-002 | EDARBI | EQ 80MG MEDOXOMIL | TABLET / ORAL | RLD, RS | 2011-02-25 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N200796-001 | EDARBI | EQ 40MG MEDOXOMIL | TABLET / ORAL | RLD | 2011-02-25 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N200796-002 | EDARBI | EQ 80MG MEDOXOMIL | TABLET / ORAL | RLD, RS | 2011-02-25 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N200796-001 | EDARBI | EQ 40MG MEDOXOMIL | TABLET / ORAL | RLD | 2011-02-25 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | N200796-002 | EDARBI | EQ 80MG MEDOXOMIL | TABLET / ORAL | RLD, RS | 2011-02-25 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N200796-001 | EDARBI | EQ 40MG MEDOXOMIL | TABLET / ORAL | RLD | 2011-02-25 | 79d66fd596c7… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N200796-002 | EDARBI | EQ 80MG MEDOXOMIL | TABLET / ORAL | RLD, RS | 2011-02-25 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N200796-001 | EDARBI | EQ 40MG MEDOXOMIL | TABLET / ORAL | RLD | 2011-02-25 | 301d65b070ca… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N200796-002 | EDARBI | EQ 80MG MEDOXOMIL | TABLET / ORAL | RLD, RS | 2011-02-25 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N200796-001 | EDARBI | EQ 40MG MEDOXOMIL | TABLET / ORAL | RLD | 2011-02-25 | 1e350fbaab3a… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N200796-002 | EDARBI | EQ 80MG MEDOXOMIL | TABLET / ORAL | RLD, RS | 2011-02-25 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N200796-001 | EDARBI | EQ 40MG MEDOXOMIL | TABLET / ORAL | RLD | 2011-02-25 | 8072bd15b7f6… | |
| 2024-05-31 18:47 UTC | 2024-05 | N200796-002 | EDARBI | EQ 80MG MEDOXOMIL | TABLET / ORAL | RLD, RS | 2011-02-25 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N200796-001 | EDARBI | EQ 40MG MEDOXOMIL | TABLET / ORAL | RLD | 2011-02-25 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N200796-002 | EDARBI | EQ 80MG MEDOXOMIL | TABLET / ORAL | RLD, RS | 2011-02-25 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N200796-001 | EDARBI | EQ 40MG MEDOXOMIL | TABLET / ORAL | RLD | 2011-02-25 | 5d02ea3f76ae… | |
| 2022-04-08 23:34 UTC | 2022-04 | N200796-002 | EDARBI | EQ 80MG MEDOXOMIL | TABLET / ORAL | RLD, RS | 2011-02-25 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N200796-001 | EDARBI | EQ 40MG MEDOXOMIL | TABLET / ORAL | RLD | 2011-02-25 | 4b0b4de00fa7… | |
| 2022-04-04 05:41 UTC | 2022-04 | N200796-002 | EDARBI | EQ 80MG MEDOXOMIL | TABLET / ORAL | RLD, RS | 2011-02-25 | 4b0b4de00fa7… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N200796-001 | AB | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N200796-002 | AB | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | N200796-001 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N200796-002 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N200796-001 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N200796-002 | AB | 1 | caaa826d4ba7… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N200796-001 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N200796-002 | AB | 1 | a50c72e98297… |
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N200796-001 | 9066936 | 2028-03-26 | Drug product | 2015-07-30 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N200796-002 | 9066936 | 2028-03-26 | Drug product | 2015-07-30 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N200796-001 | 9066936 | 2028-03-26 | Drug product | 2015-07-30 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N200796-002 | 9066936 | 2028-03-26 | Drug product | 2015-07-30 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N200796-001 | 9066936 | 2028-03-26 | Drug product | 2015-07-30 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N200796-002 | 9066936 | 2028-03-26 | Drug product | 2015-07-30 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N200796-001 | 9066936 | 2028-03-26 | Drug product | 2015-07-30 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N200796-002 | 9066936 | 2028-03-26 | Drug product | 2015-07-30 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N200796-001 | 7572920 | 2025-01-07 | U-3 | Drug product | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N200796-001 | 7157584 | 2025-05-22 | Drug substance | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N200796-001 | 9066936 | 2028-03-26 | Drug product | 2015-07-30 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N200796-002 | 7572920 | 2025-01-07 | U-3 | Drug product | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N200796-002 | 7157584 | 2025-05-22 | Drug substance | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N200796-002 | 9066936 | 2028-03-26 | Drug product | 2015-07-30 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N200796-001 | 7572920 | 2025-01-07 | U-3 | Drug product | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N200796-001 | 7157584 | 2025-05-22 | Drug substance | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | N200796-001 | 9066936 | 2028-03-26 | Drug product | 2015-07-30 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N200796-002 | 7572920 | 2025-01-07 | U-3 | Drug product | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N200796-002 | 7157584 | 2025-05-22 | Drug substance | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | N200796-002 | 9066936 | 2028-03-26 | Drug product | 2015-07-30 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N200796-001 | 7572920 | 2025-01-07 | U-3 | Drug product | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N200796-001 | 7157584 | 2025-05-22 | Drug substance | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N200796-001 | 9066936 | 2028-03-26 | Drug product | 2015-07-30 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N200796-002 | 7572920 | 2025-01-07 | U-3 | Drug product | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N200796-002 | 7157584 | 2025-05-22 | Drug substance | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N200796-002 | 9066936 | 2028-03-26 | Drug product | 2015-07-30 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N200796-001 | 7572920 | 2025-01-07 | U-3 | Drug product | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N200796-001 | 7157584 | 2025-05-22 | Drug substance | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N200796-001 | 9066936 | 2028-03-26 | Drug product | 2015-07-30 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N200796-002 | 7572920 | 2025-01-07 | U-3 | Drug product | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N200796-002 | 7157584 | 2025-05-22 | Drug substance | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N200796-002 | 9066936 | 2028-03-26 | Drug product | 2015-07-30 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N200796-001 | 7572920 | 2025-01-07 | U-3 | Drug product | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N200796-001 | 7157584 | 2025-05-22 | Drug substance | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N200796-001 | 9066936 | 2028-03-26 | Drug product | 2015-07-30 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N200796-002 | 7572920 | 2025-01-07 | U-3 | Drug product | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N200796-002 | 7157584 | 2025-05-22 | Drug substance | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N200796-002 | 9066936 | 2028-03-26 | Drug product | 2015-07-30 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N200796-001 | 7572920 | 2025-01-07 | U-3 | Drug product | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N200796-001 | 7157584 | 2025-05-22 | Drug substance | 2680178bc6a6… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Azilsartan Medoxomil | AZILSARTAN KAMEDOXOMIL | Wilshire Pharmaceuticals, Inc. | c09103d8-c094-473d-a303-bbb4f334aa8c | 2026-04-20 | Boxed warning, Warnings, Adverse reactions | 52536-004-03 52536-008-03 52536-008 52536-004 52536000403 52536000803 c09103d8-c094-473d-a303-bbb4f334aa8c c09103d8-c094-473d-a303-bbb4f334aa8c |
Adverse event summaries are temporarily unavailable. Other product information remains available.